ARHCF Stock Chart & Stats
$16.18
$0.00(0.00%)
At close: 4:00 PM EDT
$16.18
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$11.13 - $19.06
Previous CloseN/A
Volume871.00
Average Volume (3M)0.00
Market Cap
$2.55B
Enterprise Value$238.15B
Total Cash (Recent Filing)$180.61B
Total Debt (Recent Filing)$30.60B
Price to Earnings (P/E)9.5
Beta0.23
Next Earnings
Aug 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.56%
Share Statistics
EPS (TTM)150.82
Shares Outstanding191,300,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)0.91
Price to Sales (P/S)0.15
P/FCF Ratio28.53
Enterprise Value/Market Cap93.40
Enterprise Value/Revenue0.08
Enterprise Value/Gross Profit1.11
Enterprise Value/Ebitda4.32
Forecast
1Y Price Target
$14.84Price Target Upside-8.26% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.87
Revenue Forecast (FY)$19.54B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and a stronger equity base provide durable financial flexibility for a distribution business that needs to hold inventory and fund working capital. This footing reduces default risk and supports strategic investments or M&A without pressuring cash flow in downturns.
Resilient Revenue GrowthConsistent, accelerating top-line growth indicates durable demand for core pharmaceutical distribution services. Stable revenue supports scale economics in logistics and purchasing, enabling long-term customer relationships and predictable planning for the networked supply model.
Scale And Logistics-driven ModelIntegrated wholesale, logistics and inventory capabilities create structural advantages: efficient order fulfillment, manufacturer relationships and clinic/pharmacy penetration. These operational strengths raise barriers to entry and sustain recurring distribution margins over time.
Bears Say
Very Thin Operating And Net MarginsExtremely narrow margins leave earnings highly sensitive to cost increases, reimbursement shifts or pricing competition. With limited margin buffer, small adverse changes can meaningfully reduce profitability and constrain reinvestment or dividend capacity over the medium term.
Inconsistent Cash ConversionVolatile operating cash and sporadic negative free cash flow reflect working-capital swings and timing effects. This undermines reliable internal funding for capex, acquisitions or shareholder returns and increases dependence on external liquidity management even with low leverage.
Modest Returns On CapitalROE remains moderate given the capital intensity of distribution. A large asset base combined with thin margins constrains the company's ability to convert revenue into attractive shareholder returns, limiting long-term capital efficiency and reinvestment upside.
Alfresa Holdings News
ARHCF FAQ
What was Alfresa Holdings Corporation’s price range in the past 12 months?
Alfresa Holdings Corporation lowest stock price was $11.13 and its highest was $19.06 in the past 12 months.
What is Alfresa Holdings Corporation’s market cap?
Alfresa Holdings Corporation’s market cap is $2.55B.
When is Alfresa Holdings Corporation’s upcoming earnings report date?
Alfresa Holdings Corporation’s upcoming earnings report date is Aug 11, 2026 which is in 40 days.
How were Alfresa Holdings Corporation’s earnings last quarter?
Alfresa Holdings Corporation released its earnings results on May 15, 2026. The company reported $0.33 earnings per share for the quarter, beating the consensus estimate of $0.213 by $0.117.
Is Alfresa Holdings Corporation overvalued?
According to Wall Street analysts Alfresa Holdings Corporation’s price is currently Overvalued.
Does Alfresa Holdings Corporation pay dividends?
Alfresa Holdings Corporation pays a Semiannually dividend of $0.215 which represents an annual dividend yield of 3.56%. See more information on Alfresa Holdings Corporation dividends here
What is Alfresa Holdings Corporation’s EPS estimate?
Alfresa Holdings Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alfresa Holdings Corporation have?
Alfresa Holdings Corporation has 191,300,000 shares outstanding.
What happened to Alfresa Holdings Corporation’s price movement after its last earnings report?
Alfresa Holdings Corporation reported an EPS of $0.33 in its last earnings report, beating expectations of $0.213. Following the earnings report the stock price went up 1.591%.
Which hedge fund is a major shareholder of Alfresa Holdings Corporation?
Currently, no hedge funds are holding shares in ARHCF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alfresa Holdings Corporation
Alfresa Holdings Corporation, a Japanese company established in Tokyo in 2003, operates globally through its subsidiaries, specializing in the production, wholesale distribution, marketing, and international trade of pharmaceuticals, diagnostic reagents, and medical equipment. A significant part of its operations involves the wholesale supply of ethical pharmaceuticals, diagnostic reagents, and medical devices to healthcare providers including hospitals, clinics, and dispensing pharmacies. The company also manages the wholesale distribution of self-medication products, such as over-the-counter drugs, nutritional supplements, and health foods, to drugstores and pharmacies. Furthermore, Alfresa is engaged in the manufacturing and commercialization of active pharmaceutical ingredients, various pharmaceuticals, diagnostic reagents, and medical devices, alongside providing contract manufacturing services for pharmaceutical goods. Its medical-related division also encompasses the management of dispensing pharmacies and other associated healthcare activities.
ARHCF Stock 12 Month Forecast
Average Price Target
$14.84
▼(-8.26% Downside)
Technical Analysis
Medipal Holdings
―
Sundrug Co
―
Sugi Holdings Co
―
Suzuken Co
―
KUSURI NO AOKI HOLDINGS CO.,LTD.
―
Ownership Overview
―
Insiders
5.22% Mutual Funds
― Other Institutional Investors
86.31% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---



